Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
| Website | https://www.immunovant.com/join-us/values-culture |
| Revenue | $43.7 million |
| Funding | $200 million |
| Employees | 281 (224 on RocketReach) |
| Founded | 2018 |
| Address | 320 W 37th St, New York, New York 10018, US |
| Phone | +1 917-580-3099 |
| Technologies |
JavaScript
,
HTML
,
PHP
+43 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Pharmaceuticals, Healthcare |
| Competitors | Roche, Novartis, AbbVie, Sanofi, GSK, Amgen, Regeneron, Vertex Pharmaceuticals, Biogen, Receptos, a wholly-owned subsidiary of Celgene +39 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Immunovant employee's phone or email?
The Immunovant annual revenue was $43.7 million in 2026.
Eric Venker is the CEO of Immunovant.
224 people are employed at Immunovant.
Immunovant is based in New York, New York.
The NAICS codes for Immunovant are [325, 3254, 32, 32541].
The SIC codes for Immunovant are [283, 28].